Hamilton Robert J, Freedland Stephen J
Division of Urology, Duke University School of Medicine, Box 2626, Duke University Medical Center, Durham, NC 27710, USA.
Curr Urol Rep. 2008 May;9(3):189-96. doi: 10.1007/s11934-008-0034-z.
The potential ability of statin medications to prevent cancer has recently received considerable attention. Of all cancers studied, data for prostate cancer are the most promising. Results from studies examining the association between statin use and reduced risk of prostate cancer have been encouraging, particularly in terms of advanced prostate cancer risk. These findings are supported by a strong foundation of scientific evidence demonstrating the potential cholesterol and non-cholesterol-mediated mechanisms through which statins may prevent prostate cancer. In this article, we analyze recent human data regarding the association between statins and prostate cancer, and the basic scientific data supporting the possible antineoplastic mechanisms of statins. We also address the issue of where to best direct future funding and research energies. There is currently insufficient evidence to recommend all men to initiate therapy with a statin medication regardless of cholesterol profile, but the rationale to move forward with research is clear.
他汀类药物预防癌症的潜在能力最近受到了广泛关注。在所有研究的癌症中，前列腺癌的数据最具前景。研究他汀类药物使用与前列腺癌风险降低之间关联的研究结果令人鼓舞，特别是在晚期前列腺癌风险方面。这些发现得到了坚实科学证据的支持，这些证据证明了他汀类药物可能预防前列腺癌的潜在胆固醇和非胆固醇介导机制。在本文中，我们分析了关于他汀类药物与前列腺癌关联的最新人类数据，以及支持他汀类药物可能的抗肿瘤机制的基础科学数据。我们还讨论了未来资金和研究精力最佳投向的问题。目前没有足够的证据建议所有男性无论胆固醇水平如何都开始使用他汀类药物进行治疗，但推进研究的理由是明确的。
